Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01795976
Other study ID # 12_DOG14_22
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date October 2014
Est. completion date November 2017

Study information

Verified date August 2018
Source The Christie NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a trial of adoptive T cell therapy using the patient's own T cells, genetically engineered to target the tumour associated antigen NY-ESO-1 (New York esophageal squamous cell carcinoma 1). Eligible patients will undergo leukapheresis (a process to remove white blood cells) to retrieve sufficient T cells which will be gene modified and expanded in the laboratory. Patients will undergo preconditioning chemotherapy with cyclophosphamide (60mg/kg) day -7 and day -6, followed by fludarabine (25mg/m2) day -5 to day -1. The NY-ESO-1 gene modified cells will be re-infused on day 0 and the patients will receive up to 14 doses of intravenous Interleukin2 (100000 U/kg) from day 0 to day 4.

The primary objective of response rate according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 criteria will be assessed by CT scans carried out at week 6, week 12 and at 12 weekly intervals thereafter.


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date November 2017
Est. primary completion date November 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients must have histologically confirmed oesophagogastric cancer with confirmed evidence of metastatic disease and to have failed or refused standard therapies.

- There must be measurable disease

- Patients may have had any previous systemic therapies provided they are otherwise fit for treatment

- Age equal to or greater than 18 years

- World Health Organisation (WHO) performance status of 0 or 1

- Patients must be HLA-A2 positive

- Their tumour must stain positive by immunohistochemistry for NY-ESO-1 (either diagnostic or more recent biopsy is acceptable)

- Life expectancy >3months

- Left ventricular ejection fraction (LVEF) > 50% as measured by ECHO or Multi Gated Acquisition Scan (MUGA)

- Haematological and biochemical indices:

- Haemoglobin (Hb) = 8.0 g/dL

- Neutrophils = 1.0 x 10*9/L

- Platelets (Plts) = 100 x 10*9/L

- Any of the following abnormal baseline liver function tests:

- serum bilirubin = 20 mmol/l (ULN)

- alanine aminotransferase (ALT) and/or

- aspartate aminotransferase (AST) and/or

- = 3 x ULN unless patient has liver metastases when can be < 5 x ULN.

- Serum creatinine = 0.15 mmol/L or creatinine clearance > 50 ml/min

- These measurements must be performed prior to leukaphereses and again prior to commencing preconditioning chemotherapy.

- The chemotherapy to be used in this trial is non-myeloablative, but where patients have had previous high dose chemotherapy, an autologous haemopoietic stem cell backup harvest, for stem cell rescue, will be obtained prior to commencing therapy in this trial. Similarly, where there is concern about a patient's bone marrow reserves, for example due to multiple previous lines of myelosuppressive chemotherapy a backup stem cell harvest should also be obtained.

- Female patients of child-bearing potential must have a negative serum or urine pregnancy test prior treatment and agree to use appropriate medically approved contraceptive precautions for four weeks prior to entering the trial, during the trial, and for six months afterwards.

- Male patients must agree to use barrier method contraception during the treatment and for six months afterwards.

- Able to provide full written informed consent.

Exclusion Criteria:

- Those receiving radiotherapy, biological therapy, endocrine therapy, immunotherapy, systemic steroids, or chemotherapy during the previous four weeks (six weeks for nitrosoureas and Mitomycin-C) prior to treatment or during the course of the treatment.

- All toxic manifestations of previous treatment must have resolved. Exceptions to this are alopecia or certain Grade 1 toxicities, which an investigator considers should not exclude the patient.

- Participation in any other clinical trial within the previous 30 days or during the course of this treatment.

- Previous allogeneic transplant.

- Clinically significant cardiac disease.

- Patients who are high medical risks because of non-malignant systemic disease, including those with active infection, uncontrolled cardiac or respiratory disease, or other serious medical or psychiatric disorders which in the lead clinicians opinion would not make the patient a good candidate for adoptive T-cell therapy.

- Concurrent serious infections within the 28 days prior to treatment

- Current malignancies at other sites, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin.

- Patients known or found to be serologically positive for Hepatitis B, C, HIV or Human T cell lymphotropic Virus (HTLV).

- History of systemic autoimmune disease which could be life-threatening if reactivation occurred( for example hypothyroidism would be permissible, prior rheumatoid arthritis or systemic lupus erythematosus (SLE0 would not).

- Evidence of Centra Nervous System (CNS) involvement.

- Patients who are likely to require systemic steroids or other immunosuppressive therapy.

- Pregnant and lactating women.

- Radiotherapy to >25% skeleton.

Study Design


Related Conditions & MeSH terms


Intervention

Genetic:
NY-ESO-1 T cells

Drug:
cyclophosphamide
cyclophosphamide 60mg/kg/day day -7 and day -6
Fludarabine
Fludarabine given 25mg/m2 day -5 to day -1
Biological:
Interleukin 2
Interleukin 2 (IL2) immunotherapy given day 0 to day 6

Locations

Country Name City State
United Kingdom The Christie NHS Foundation Trust Manchester

Sponsors (7)

Lead Sponsor Collaborator
Fiona Thistlethwaite Erasmus Medical Center, Karolinska University Hospital, Ospedale San Raffaele, The Christie NHS Foundation Trust, The Netherlands Cancer Institute, University College London Hospitals

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other modified T-cell survival Laboratory analysis of gene modified T-cell survival and other immunological assessments 24 weeks post cell infusion
Other Evaluation of Tumour marker responses. Measuring NY-ESO levels via blood test 24 weeks post T-cell infusion
Primary Response rate to New York esophageal squamous cell carcinoma (NYESO) T cells To evaluate the response rate in Oesophagogastric cancer patients who are New York esophageal squamous cell carcinoma 1 (NY-ESO-1)and Human Leukocyte Antigen serotype "A" serotype group (HLA-A2) positive to adoptive cell therapy targeted to NY-ESO-1. 6 weeks post treatment
Primary Response rate to NYESO T cells To evaluate the response rate in Oesophagogastric cancer patients who are NY-ESO-1 and HLA-A2 positive to adoptive cell therapy targeted to NY-ESO-1. 12 weeks post treatment
Primary Response rate to NYESO T cells To evaluate the response rate in Oesophagogastric cancer patients who are NY-ESO-1 and HLA-A2 positive to adoptive cell therapy targeted to NY-ESO-1. 24 weeks post treatment
Primary Response rate to NYESO T cells To evaluate the response rate in Oesophagogastric cancer patients who are NY-ESO-1 and HLA-A2 positive to adoptive cell therapy targeted to NY-ESO-1. 36 weeks post treatment
Primary Response rate to NYESO T cells To evaluate the response rate in Oesophagogastric cancer patients who are NY-ESO-1 and HLA-A2 positive to adoptive cell therapy targeted to NY-ESO-1. 48 weeks post treatment
Secondary Feasibility and tolerability of NY-ESO-1 targeted cell therapy Evaluation of feasibility and tolerability of adoptive cell therapy targeted to NY-ESO-1 in Oesophagogastric cancer patients who are NY-ESO-1 and HLA-A2 positive. Feasibility will be assessed proceed to full therapy (Study day 6).
Secondary Evaluation of the progression free survival measuring length of time from point of cell infusion until disease progression. Until progression occurs, estimated to be average of 12 months per patient.
Secondary Feasibility and tolerability of NY-ESO-1 targeted cell therapy Evaluation of feasibility and tolerability of adoptive cell therapy targeted to NY-ESO-1 in Oesophagogastric cancer patients who are NY-ESO-1 and HLA-A2 positive. Tolerability will be assessed for follow-up period, estimated to be average of 12 months per patient.
See also
  Status Clinical Trial Phase
Recruiting NCT05685862 - Laser Speckle Contrast Imaging, Surgical Eye & ICG Fluorescence Imaging for Perfusion Assessment of the Gastric Conduit
Recruiting NCT01795768 - Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours Phase 2
Completed NCT05266300 - Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.
Recruiting NCT03978377 - Cardiopulmonary Toxicity of Thoracic Radiotherapy
Active, not recruiting NCT03653052 - Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab Phase 2
Recruiting NCT05489250 - The PLATON Network
Recruiting NCT04484636 - PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study) N/A
Recruiting NCT01843829 - A Feasibility Study of Chemo-radiotherapy to Treat Operable Oesophageal Cancer Phase 2
Completed NCT02382237 - Comparison of Tumor Glucose Metabolism Before and After Artificial Nutrition N/A
Completed NCT01915693 - ROCS (Radiotherapy After Oesophageal Cancer Stenting) Study Phase 3
Recruiting NCT04517448 - Quality of Life of Patients Over 75 Yars Undergoing Palliative Chemotherapy
Recruiting NCT04232735 - Evidence Based Information Provision to Improve Decision Making After Oesophagogastric Cancer Diagnosis (SOURCE) N/A
Recruiting NCT05642819 - REVOLUTION Surgery (REVOLUTION Surgery)
Recruiting NCT04001478 - Non-invasive Testing for Early oEesophageal Cancer and Dysplasia
Recruiting NCT02741856 - Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation Phase 2/Phase 3
Not yet recruiting NCT05600608 - Augmentation of Volatile Biomarkers of Oesophageal and Gastric Adenocarcinoma From the Tumour Lipidome N/A
Recruiting NCT04481256 - TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY N/A
Recruiting NCT05057013 - HMBD-001 in Advanced HER3 Positive Solid Tumours Phase 1/Phase 2
Not yet recruiting NCT06046846 - Prehabilitation Via a Mobile Application in Oesophago-gastric Cancer N/A
Recruiting NCT05357846 - PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101) Phase 3